Posted on

Check Out These 3 Midweek Penny Stocks Before It’s Too Late

617 Views
0 Total shares
penny stocks

The SEC (Securities and Exchange Commision) labels penny stocks as equities trading under $5 dollars. Did you know that? Penny stocks can sometimes have a negative connotation, but simply, they are just smaller priced than a lot of the bigger name stocks out there.

Typically, when it comes to higher priced “Blue Chip” stocks, they are not capable of making big double-digit moves during a single day. Blue-chip stocks are for the most part large-cap stocks, which typically means they have a market valuation of $10Bn or even more. Penny stocks, on the other hand, are often more capable of making big short-term swings of double-digit or even triple-digit proportions. Because of this, they are highly risky, but can also be highly rewarding.

Read More: What’s On Your Watch-list? Here Are 3 Penny Stocks To Consider

In case you haven’t been doing this for long, or have taken a break over the past several months, penny stocks have been on the surge. Trying to narrow down why this has happened, I’m under the impression that retail investors may be the cause. Due to the Covid-19 restrictions for the most part keeping people stuck in their houses, these same people have looked for a new outlet to make money. Because of this, penny stocks have been red-hot as new money has been flooding the market. And, with today’s news, these 3 penny stocks could be the next to burst.

Your No. 1 Midweek Penny Stock To Watch: DPW Holdings, Inc.

DPW Holdings, Inc. (NYSE American: DPW), through its subsidiaries, designs, develops, manufactures, and sells power system solutions for the military/aerospace, medical, and industrial-telecommunication industries in North America, Europe, the Middle East, and internationally. The company offers custom power system solutions; high-grade flexibility series power supply products, such as power rectifiers; and value-added services for original equipment manufacturers. It also provides power conversion and distribution equipment, direct current/active current inverters, and uninterrupted power supply (UPS) products; and radio frequency and microwave filters, diplexers, multiplexers, detectors, switch filters, integrated assemblies, and detector logarithmic video amplifiers, as well as provides commercial loans and operates MonthlyInterest.com, an online fintech portal.

DPW Holdings, Inc. announced that its global defense business, Gresham Worldwide, Inc. (“Gresham Worldwide”), has recently received purchase orders totaling approximately $3.2 million from four different global defense contractor customers of its operating subsidiary Microphase Corporation (“Microphase”).

Gresham Worldwide provides high-quality, highly reliable bespoke technology solutions for mission critical applications in the defense, public safety, homeland security, medical and telecommunications markets. Microphase designs, develops, and manufactures standard and customized state-of-the-art RF, microwave, and millimeter-wave components, devices, subsystems and integrated modules for the worldwide defense and aerospace, satellite, wireless multimedia and consumer electronics, public safety and Homeland Security markets. Microphase will perform and deliver on these recent orders over the remainder of calendar 2020 and throughout 2021.

We strongly believe in  the prospects for Gresham Worldwide,” said Jonathan Read, Gresham Worldwide’s CEO. “Demand for Gresham’s technology offerings remains strong. This recent uptick in orders reflects the confidence and the trust that Gresham has with long life cycle platform programs of ‘blue chip’ customers in defense, aerospace and commercial sectors across the globe. We anticipate that strong demand and customer confidence will enable us to achieve significant growth in 2020 and 2021.”

DPW’s CEO and Chairman, Milton “Todd” Ault, III said, “We are pleased to see the positive development of our defense business, which demonstrates the progress we are making in achieving our goals. In conjunction with our corporate realignment, we are committed to redeploying existing assets and resources with greater efficiency to take DPW on a path to increased revenue generation and improvements to its bottom line. DPW has stepped up its focus on managing and financially supporting our Gresham Worldwide global defense business with the goal of maximizing the value returned to shareholders.”

Your No. 2 Midweek Penny Stock To Watch: InspireMD, Inc.

InspireMD, Inc. (NYSE American: NSPR), a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms.

InspireMD, Inc. announced that 12-month PARADIGM trial results have been published in the EuroIntervention journal. The paper, entitled, “Routine MicroNET™ covered embolic prevention stent system use for consecutive symptomatic and increased stroke-risk asymptomatic carotid stenosis revascularization: Twelve-month outcomes from the PARADIGM study,” details the results of 101 unselected consecutive real-life patients treated with the CGuard™ MicroNET covered stent for carotid stenosis and the 12-month prevention of postprocedural neurologic events.

101 unselected consecutive patients for carotid revascularization were enrolled in the PARADIGM trial. At 30 days, only one adverse event occurred (a minor transient stroke with no other strokes, myocardial infarctions, or deaths. Furthermore, these study results show that no strokes occurred between 30 days and twelve months.

“PARADIGM evaluates CGuard™ in unselected consecutive patients for carotid revascularization, with higher clinical standards, and constitutes a reference for future carotid stenting studies,” said Marvin Slosman, Chief Executive Officer of InspireMD. “This is substantiated by a new paper in EuroIntervention, a prestigious medical journal covering the latest advancements in vascular intervention. The risk of peri-procedural or post-procedural stroke in the treatment of carotid stenotic lesions has long been a significant obstacle to more widespread adoption of less invasive stenting as an alternative to surgery for carotid revascularization. We believe these new data demonstrate the sustained safety of our unique CGuard™ EPS system incorporating proprietary MicroNet™ technology. Data such as these are integral to our ongoing efforts to make CGuard™ the eventual standard of care because of the many clinical benefits of CGuard™.

“Our present work indicates that an effective MicroNET™-covered stent protection against post-procedural neurologic events extends at least mid-term in the absence of any procedure- or device-related issues,” stated Dr. Piotr Musialek, co-author of the paper and lead investigator of the PARADIGM study.

Your No. 3 Midweek Penny Stock To Watch: Curis, Inc.

Curis, Inc. (Nasdaq: CRIS), a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.

The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology.

Curis, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Curis plans to initiate a Phase 1a/1b study of CI-8993 in the second half of 2020.

“The clearance of our IND is an important step for the advancement of VISTA therapies, as CI-8993 becomes the first anti-VISTA antibody in development to enter clinical testing,” said James Dentzer, President and Chief Executive Officer of Curis. “When activated, VISTA plays a critical role in suppressing T cell activity. Conversely, it has been shown in preclinical studies that blocking VISTA reduces the suppression of T cells and reactivates anti-tumor immune function. We are eager to leverage our extensive experience with VISTA and pioneer this first-in-class anti-VISTA antibody program.”

Certain cancers, such as mesothelioma, triple negative breast cancer, non-small cell lung cancer, and gynecologic malignancies, are known to be highly driven by VISTA. These cancers may be amenable to monotherapy treatment with anti-VISTA therapy.

In other cancers, anti-VISTA therapy may be more effective as part of a combination approach. VISTA is independent of, and complementary to, other immune checkpoints, including PD1 and CTLA4. Published studies have shown that VISTA expression increases up to 5-fold as a compensatory mechanism following anti-CTLA4 or anti-PD1 treatment. Further preclinical studies have explored this relationship more deeply and support the potential of combining anti-VISTA therapy with anti-PD1 or anti-CTLA4 therapies.

The multi-center, open-label Phase 1a/1b dose escalation study of CI-8993 in patients with relapsed / refractory solid tumors will evaluate approximately 50 patients, with the goal of identifying a recommended dose and schedule. Curis expects to initiate this study in the second half of 2020.

Daily updates